Last reviewed · How we verify
Beclometasone/Formoterol/Glycopyrrolate
Beclometasone/Formoterol/Glycopyrrolate is a Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment. Also known as: BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 mcg, CHF 5993 pMDI, CHF5993 pMDI.
This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.
This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Beclometasone/Formoterol/Glycopyrrolate |
|---|---|
| Also known as | BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 mcg, CHF 5993 pMDI, CHF5993 pMDI |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) |
| Target | Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrrolate) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclometasone suppresses inflammatory responses in the airways by binding glucocorticoid receptors. Formoterol activates beta-2 adrenergic receptors to produce sustained bronchodilation. Glycopyrrolate blocks muscarinic acetylcholine receptors to provide additional bronchospasm relief. Together, these three agents address inflammation, acute bronchoconstriction, and sustained airway obstruction in chronic obstructive pulmonary disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Oral candidiasis
- Upper respiratory tract infection
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (PHASE2)
- Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (PHASE3)
- Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclometasone/Formoterol/Glycopyrrolate CI brief — competitive landscape report
- Beclometasone/Formoterol/Glycopyrrolate updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Beclometasone/Formoterol/Glycopyrrolate
What is Beclometasone/Formoterol/Glycopyrrolate?
How does Beclometasone/Formoterol/Glycopyrrolate work?
What is Beclometasone/Formoterol/Glycopyrrolate used for?
Who makes Beclometasone/Formoterol/Glycopyrrolate?
Is Beclometasone/Formoterol/Glycopyrrolate also known as anything else?
What drug class is Beclometasone/Formoterol/Glycopyrrolate in?
What development phase is Beclometasone/Formoterol/Glycopyrrolate in?
What are the side effects of Beclometasone/Formoterol/Glycopyrrolate?
What does Beclometasone/Formoterol/Glycopyrrolate target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) drugs
- Target: All drugs targeting Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrrolate)
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Also known as: BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 mcg, CHF 5993 pMDI, CHF5993 pMDI
- Compare: Beclometasone/Formoterol/Glycopyrrolate vs similar drugs
- Pricing: Beclometasone/Formoterol/Glycopyrrolate cost, discount & access